BioSpace News Archive

“I thought there could be a better way to prevent skin contact with urine for men wearing disposable diapers,” said an inventor, from Florence, S.C., “so I invented the C-POUCH.”

Paylogix participated as a team in the 25th Annual Making Strides Against Breast Cancer Walk in Jones Beach on October 21st.

The Quick Group has entered into an agreement to be acquired by Kuehne + Nagel, one of the world’s leading logistics companies in the airfreight, seafreight, contract logistics, and overland businesses.

- Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) approved DAURISMO™ (glasdegib), a once-daily oral medicine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are 75 years or older or who have comorbidities that preclude use of intensive induction chemotherapy.

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to VENCLEXTA® (venetoclax tablets) in combination with azacitidine, or decitabine, or low-dose cytarabine (LDAC) for the treatment of newly-diagnosed acute myeloid leukemia

Castle Biosciences, Inc. today announced that Derek Maetzold, President and CEO, will present a company overview at the 30th Annual Piper Jaffray Healthcare Conference on Wednesday, November 28th, 2018 at 10:10 a.m. EST in New York City.

This notice has been updated to include an additional case of E. coli linked to the outbreak that has been reported in New Brunswick. There are now 19 confirmed cases in Canada. The public health advice included in this notice now applies to residents in New Brunswick.

Sage Therapeutics today announced that the Company will present at the Piper Jaffray 30th Annual Healthcare Conference on Wednesday, November 28, 2018 at 09:30 A.M. ET in New York, NY.

Single Phase 3 Clinical Trial May be Sufficient for Approval for Prevention of Antibiotic-Mediated Clostridium difficile Infection (CDI)

Proteostasis is a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis and other diseases caused by dysfunctional protein processing